Michael Thomas Henderson's Net Worth

$82.4 Million

Estimate Recalculated Sep 17, 2024 05:46PM EST

Who is Michael Thomas Henderson?

Michael Thomas Henderson has an estimated net worth of $82.4 Million. This is based on reported shares across multiple companies, which include BridgeBio Pharma, Inc., ARYA Sciences Acquisition Corp IV, Spyre Therapeutics, Inc., and Apogee Therapeutics, Inc..

SEC CIK

Michael Thomas Henderson's CIK is 0001779990

Past Insider Trading and Trends

2020 was Michael Thomas Henderson's most active year for acquiring shares with 27 total transactions. Michael Thomas Henderson's most active month to acquire stocks was the month of April. 2020 was Michael Thomas Henderson's most active year for disposing of shares, totalling 51 transactions. Michael Thomas Henderson's most active month to dispose stocks was the month of June. 2019 saw Michael Thomas Henderson paying a total of $119,000.00 for 180,767 shares, this is the most they've acquired in one year. In 2024 Michael Thomas Henderson cashed out on 125,000 shares for a total of $4,088,505.09, their largest year based on trade value.

Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

BridgeBio Pharma, Inc. (BBIO) Snapshot price: $30.7

Chief Business Officer

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
—
0
—
—
0
Dec 15
Form 4
—
0
$26.29
-$504,704.08
274.21K
Scheduled
Dec 1
Form 4
-0.30%
-784.00
$30.04
-$23,548.54
261.4K
Scheduled
Jun 3
Form 4
+2.41%
6.46K
$22.90
-$731,628.49
274.21K
Scheduled
Nov 16
Form 4
—
0
$19.70
-$373,057.65
267.75K
Scheduled
Nov 2
Form 4
—
0
$19.81
-$380,348.18
267.75K
Scheduled
Oct 1
Form 4
—
0
$20.11
-$397,788.12
267.75K
Scheduled
Sep 18
Form 4
—
0
$14.45
-$285,734.39
267.75K
Scheduled
Sep 1
Form 4
+2.82%
7.35K
$28.53
-$155,773.80
267.75K
Aug 16
Form 4
—
0
$13.77
-$272,140.73
260.29K
Scheduled
Aug 3
Form 4
—
0
$15.57
-$308,101.26
260.29K
Scheduled
Jul 1
Form 4
-0.23%
-606.00
$30.01
-$18,185.25
260.29K
Scheduled
Jun 8
Form 4
-0.98%
-2.58K
$29.37
-$75,911.65
261.68K
Scheduled
Jun 1
Form 4
+7.47%
18.36K
$1.05
$19,283.25
264.27K
May 26
Form 4
+51.45%
83.54K
—
—
245.9K
May 19
Form 4
-0.89%
-1.46K
$30.47
-$44,493.35
162.36K
Scheduled
May 5
Form 4
-2.33%
-3.90K
$29.52
-$115,266.78
163.82K
Scheduled
May 1 - May 4
Form 4
-1.52%
-2.58K
$26.94
-$69,629.23
167.73K
Scheduled
Apr 1
Form 4
-2.28%
-3.98K
$32.44
-$128,965.21
170.31K
Scheduled
Mar 2
Form 4
-2.23%
-3.98K
$34.90
-$138,729.49
174.29K
Scheduled
Feb 3
Form 4
-2.18%
-3.98K
$33.17
-$131,861.08
178.26K
Scheduled
Jan 2 - Jan 3
Form 4
∞
180.77K
$17.00
—
180.77K
Jul 1
Form 3
—
0
—
—
0
No matching records found

ARYA Sciences Acquisition Corp IV (ARYD) No price found

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
—
0
—
—
0
Jul 31
Form 3
—
0
—
—
0
No matching records found

Spyre Therapeutics, Inc. (AGLE) No price found

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
—
0
—
—
0
May 14
Form 3
—
0
—
—
0
No matching records found

Apogee Therapeutics, Inc. (APGE) Snapshot price: $47.25

Chief Executive Officer

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-2.79%
-40.00K
$47.62
-$1,904,841.05
1.39M
Scheduled
Sep 4
Form 4
-2.71%
-40.00K
$40.62
-$1,624,764.04
1.43M
Scheduled
Aug 7
Form 4
-1.01%
-15.00K
$37.26
-$558,900.00
1.47M
Scheduled
Jul 5
Form 4
—
0
—
—
0
Dec 18
Form 3/A
—
0
—
—
0
Form 3
—
0
—
—
0
No matching records found